Serina Therapeutics Q2 net loss widens on higher expenses
SERA•Overview
- US biotech firm reported no Q2 revenue and a wider net loss yr/yr
- Q2 operating expenses rose due to higher R&D and legal costs
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Income From Operations | -$6.78 mln | ||
| Q2 Operating Expenses | $6.78 mln |
Result drivers
- R&D spending - Co said higher Q2 R&D expenses were driven by increased headcount and greater clinical-related activity
- Legal and financing costs - Co attributed higher Q2 general and administrative expenses to legal expenses associated with patent and financing activities
Analyst coverage
- The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy."
- Wall Street's median 12-month price target for Serina Therapeutics, Inc. is $9.50, about 236.9% above its August 12 closing price of $2.82
